- #36
- 3,759
- 4,199
Here's a section from a niece Perspective piece published in Nature outlining some scenarios for what SARS-CoV-2 looks like going into the future:
The full article is relevant to the discussion as it talks about how the virus can persist as an endemic virus through pockets of susceptible individuals and waning immunity after infection or vaccination, changes in the virus through antigenic drift that diminish protection, and reentries from zoonotic reservoirs, pulling upon our experiences with other similar viruses like influenza.
https://www.nature.com/articles/s41586-021-03792-wThe first – and most worrisome – scenario is that we will not gain rapid control of this pandemic and thus will face a future with ongoing severe disease manifestations combined with high levels of infected individuals which, in turn, might foster further evolution of the virus. Vaccinations and prior infection might achieve long term herd immunity, but we will need a very broad application of vaccines worldwide combined with comprehensive disease surveillance by accurate and readily available diagnostic assays or devices76.
A second and more likely scenario is the transition to an epidemic seasonal disease like influenza. Effective therapies that prevent progression of COVID-19 disease (e.g., monoclonal antibodies reduce hospitalization and death by 70-85%) may bring the burden of SARS-CoV-2 infection to levels that are equivalent or even lower than influenza. However, we should remember that the annual mortality burden of influenza, in non-pandemic years, is estimated to be 250,000 to 500,000, with up to 650,000 all-cause deaths globally, comprising ~2% of all annual respiratory deaths (two thirds among people 65 years and older)77. This is an extremely significant health burden and equates to a relatively ‘optimistic’ view of the future of the SARS-CoV-2 pandemic.
A third scenario is the transition to an endemic disease similar to other human Coronavirus infection that have a much lower disease impact than influenza or SARS-CoV-2. There is, however, limited data on the global burden of disease by common human coronaviruses78 and as noted in earlier sections, it is not possible to predict with confidence whether further adaptations of SARS-CoV-2 to humans will increase or decrease its intrinsic virulence.
The full article is relevant to the discussion as it talks about how the virus can persist as an endemic virus through pockets of susceptible individuals and waning immunity after infection or vaccination, changes in the virus through antigenic drift that diminish protection, and reentries from zoonotic reservoirs, pulling upon our experiences with other similar viruses like influenza.